NEW YORK, April 18 - Qiagen said today it has bought Xeragon for about $8 million as part of its goal of expanding its oligonucleotide business.

Qiagen paid for the deal by issuing 564,000 shares in exchange for all of the outstanding capital stock of Xeragon. Qiagen said it may issue an additional payment of up to $1.2 million in cash or stock if certain performance targets are met by next December.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.